Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for injection use. It is employed to manage autoimmune conditions such as rheumatoid arthritis and psoriasis, as well as certain cancers including acute lymphoblastic leukemia and osteosarcoma.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Methotrexate is used in autoimmune and oncologic disease pathways to modify disease activity and control cell proliferation.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin lesion severity and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Osteosarcoma: inhibits tumor growth as part of multi‑agent chemotherapy.

Methotrexate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring in many patients. - Fatigue: persistent tiredness or reduced energy. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic enzyme rise. - Low blood cell counts: mild anemia, leukopenia or thrombocytopenia.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: reduced kidney function. - Severe bone marrow suppression: pancytopenia. - Opportunistic infections: due to immunosuppression.

When prescribing methotrexate, clinicians should observe several safety precautions to minimize risks.

- Baseline assessment: obtain liver function tests, renal function and complete blood count before initiation. - Monitoring: repeat laboratory evaluations regularly to detect toxicity early. - Contraindications: avoid in patients with severe hepatic disease or active infections. - Pregnancy risk: discontinue in women planning conception and use effective contraception. - Drug interactions: review concomitant medications that may increase toxicity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several agents that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce renal clearance and raise methotrexate levels. - Proton pump inhibitors: may impair renal elimination. - Penicillins (e.g., ampicillin): can decrease methotrexate excretion.

Moderate Interactions (Monitor Closely): - Sulfonamides and trimethoprim: may enhance myelosuppression. - Live vaccines: increased risk of infection due to immunosuppression. - Alcohol: can exacerbate liver toxicity.